Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $12.5 million.

  • Ani Pharmaceuticals' Other Non-Current Assets rose 901.08% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 901.08%. This contributed to the annual value of $12.2 million for FY2024, which is 122.6% up from last year.
  • Ani Pharmaceuticals' Other Non-Current Assets amounted to $12.5 million in Q3 2025, which was up 901.08% from $8.2 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Other Non-Current Assets ranged from a high of $16.1 million in Q3 2023 and a low of $5.0 million during Q1 2021
  • In the last 5 years, Ani Pharmaceuticals' Other Non-Current Assets had a median value of $11.4 million in 2022 and averaged $9.9 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first surged by 17141.62% in 2023, then tumbled by 3581.88% in 2025.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Other Non-Current Assets stood at $5.0 million in 2021, then surged by 127.17% to $11.4 million in 2022, then grew by 6.26% to $12.1 million in 2023, then grew by 1.23% to $12.2 million in 2024, then increased by 2.27% to $12.5 million in 2025.
  • Its Other Non-Current Assets was $12.5 million in Q3 2025, compared to $8.2 million in Q2 2025 and $10.3 million in Q1 2025.